yingweiwo

IXAZOMIB (MLN2238)

Alias: MLN-2238; MLN2238; IXAZOMIB; MLN 2238; Trade name: Ninlaro
Cat No.:V0688 Purity: ≥98%
Ixazomib (formerly also known as MLN-2238) is a novel, potent, selective and reversible proteasome inhibitor (PI) with potential antineoplastic activity.
IXAZOMIB (MLN2238)
IXAZOMIB (MLN2238) Chemical Structure CAS No.: 1072833-77-2
Product category: Proteasome
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

Other Forms of IXAZOMIB (MLN2238):

  • Ixazomib citrate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Ixazomib (formerly also known as MLN-2238) is a novel, potent, selective and reversible proteasome inhibitor (PI) with potential antineoplastic activity. It also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM, respectively. In cell-free assays, it inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome. In both the OCI-Ly10 and PHTX22L models, MNL-2238, the biologically active form of MLN9708, exhibits better antitumor activity and a better pharmacodynamic profile than bortezomib.

Biological Activity I Assay Protocols (From Reference)
Targets
20S proteasome (IC50 = 3.4 nM); 20S proteasome (Ki = 0.93 nM)
ln Vitro
MLN2238 also inhibits the trypsin-like (β2) and caspase-like (β1) proteolytic sites at higher concentrations (IC50 = 3.5uM and 31nM, respectively). Calu-6 cell inhibition by MLN2238 has an IC50 of 9.7 nM. The proteasome in tumor cells is selectively, potently, and reversibly inhibited by MLN2238. Time-dependent reversible proteasome inhibition is demonstrated by MLN2238. Time-dependent reversible proteasome inhibition is demonstrated by both MLN2238 and Bortezomib; however, MLN2238's proteasome dissociation half-life is approximately six times faster than Bortezomib's (18 and 110 minutes, respectively). In line with the quicker recovery of proteasome activity seen in the Proteasome-Glo assay, MLN2238 dissociates from the proteasome more quickly than Bortezomib. 20S inhibition indicates that MLN2238 has a higher overall tumor pharmacodynamic effect than Bortezomib. (Source: ) The form of MLN9708 that is biologically active is MLN2238.[2]
ln Vivo
MLN2238 causes xenograft tumors to respond more pharmacologically than Bortezomib. In comparison to Bortezomib, MLN2238 exhibits higher maximum and sustained tumor proteasome inhibition in xenograft models. These findings verify that enhanced tumor exposure observed with MLN2238 corresponds to an enhanced tumor pharmacodynamic response, both upstream and downstream of the proteasome. The CWR22 xenograft model demonstrates antitumor activity for MLN2238. In WSU-DLCL2 xenografts, MLN2238 exhibits higher tumor pharmacodynamic responses than boratezomib. Similarly, GADD34 expression is strongly induced by MLN2238, but Bortezomib treatment only slightly raised GADD34 levels in WSU-DLCL2 xenograft tumors.[1] In both the PHTX22L and OCI-Ly10 models, MLN2238 exhibits a better antitumor activity and pharmacodynamic profile than Bortezomib.[2]
Enzyme Assay
One day prior to the commencement of the experiment, Calu-6 cells are plated at a density of 1 × 104 cells per well in a 384-well plate, grown in MEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Using the Proteasome-Glo assay reagents in accordance with the manufacturer's instructions, proteasome activity is measured by tracking hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase. An apparatus called a LEADseeker is used to measure luminosity.
Cell Assay
A day prior to the commencement of the experiment, 1 × 104 cells are plated in each well of a 384-well plate using Calu-6 cells that have been cultured in MEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells are treated for one hour at 37 °C with different doses of MLN2238 or boratezomib in 0.5% final v/v DMSO for IC50 calculations. To conduct reversibility tests, cells are exposed to 1 μM Bortezomib or MLN2238 for thirty minutes at 37 °C. Following treatment, the cells are triple-washed in medium to eliminate the Bortezomib or MLN2238. After four more hours of incubation at 37 °C, the medium is removed from the cells and replaced with new medium.
Animal Protocol
Mice: Male CB17-SCID mice are injected subcutaneously (s.c.) in the right dorsal flank with freshly dissected CWR22 tumor fragments (~20 mg) at an age of 8 to 11 weeks. The formula to calculate the mean tumor volume (MTV) is 0.5×(length×width2). Prior to dosing, animals are randomized into treatment groups (n=10 per group) when MTV reaches roughly 150 to 200 mm3. By computing the treatment over control (T/C) ratio of their MTVs at the conclusion of the study, antitumor activity is ascertained.
Rats: Ixazomib (MLN2238) at 0.3 or 0.2 mg/kg or Bortezomib at 0.2 mg/kg is given intravenously (i.v.) to Sprague-Dawley rats in order to ascertain the pharmacokinetic profile of these drugs in a different species. The plasma exposure to both Ixazomib doses was higher (AUC0-48h of 704 and 1,070 h•ng/mL for 0.2 and 0.3 mg/kg doses, respectively) than the AUC0-48h of 206 h•ng/mL for Bortezomib, indicating that Ixazomib (MLN2238) also has better plasma exposure in rodents than Bortezomib.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%.
62% in urine and 22% in feces.
The steady-state volume of distribution is 543 L.
Metabolism / Metabolites
Metabolism of ixazomib is expected to be by CYP and non-CYP pathways, with no predominant CYP isozyme contribution. At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (<1%).
Biological Half-Life
Terminal half-life is 9.5 days.
Toxicity/Toxicokinetics
Hepatotoxicity
In large clinical trials of ixazomib combined with lenalidomide and dexamethasone, elevations in serum aminotransferase levels were common, occurring in ~10% of patients. However, values greater than 5 times the upper limit of normal (ULN) were rare, occurring in
Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
No information is available on the clinical use of ixazomib during breastfeeding. Because its half-life is about 9.5 days, it is likely to accumulate in the infant. It is also given in combination with leflunomide and dexamethasone, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during ixazomib therapy and for 90 days after the last dose.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
99%
References

[1]. Cancer Res . 2010 Mar 1;70(5):1970-80.

[2]. Clin Cancer Res . 2011 Dec 1;17(23):7313-23.

Additional Infomation
Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. It has a role as an apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It is a member of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids.
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Ixazomib is a Proteasome Inhibitor. The mechanism of action of ixazomib is as a Proteasome Inhibitor.
Ixazomib is a small molecule proteasome inhibitor that is used in combination with other antineoplastic agents to treat refractory multiple myeloma. Ixazomib is associated with a low rate of serum enzyme elevations during treatment and to rare instances of clinically apparent, acute liver injury.
Ixazomib is an active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.
See also: Ixazomib Citrate (active moiety of).
Drug Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
FDA Label
Treatment of lymphoid malignancies (excluding multiple myeloma), Treatment of multiple myeloma
Mechanism of Action
Ixazomib is an N-capped dipeptidyl leucine boronic acid which reversibly inhibits the CT-L proteolytic (β5) site of the 20S proteasome. At higher concentrations, ixazomib also seems to inhibit the proteolytic β1 and β2 subunits and to induce accumulation of ubiquitinated proteins.
Pharmacodynamics
In vitro studies have shown ixazomib to induce apoptosis in multiple myeloma cells sensitive or resistant to other conventional therapies. In mouse xenograft models, ixazomib induced tumor growth inhibition.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C14H19BCL2N2O4
Molecular Weight
361.03
Exact Mass
360.081
Elemental Analysis
C, 46.58; H, 5.30; B, 2.99; Cl, 19.64; N, 7.76; O, 17.73
CAS #
1072833-77-2
Related CAS #
Ixazomib citrate;1239908-20-3
PubChem CID
25183872
Appearance
Solid powder
Density
1.3±0.1 g/cm3
Index of Refraction
1.546
LogP
2.82
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
7
Heavy Atom Count
23
Complexity
412
Defined Atom Stereocenter Count
1
SMILES
ClC1C([H])=C([H])C(=C([H])C=1C(N([H])C([H])([H])C(N([H])[C@]([H])(B(O[H])O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)=O)Cl
InChi Key
MXAYKZJJDUDWDS-LBPRGKRZSA-N
InChi Code
InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
Chemical Name
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
Synonyms
MLN-2238; MLN2238; IXAZOMIB; MLN 2238; Trade name: Ninlaro
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~72 mg/mL (~199.4 mM)
Water: <1 mg/mL
Ethanol: ~9 mg/mL (~24.9 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 0.5% hydroxyethyl cellulose: 30 mg/mL

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.7699 mL 13.8493 mL 27.6985 mL
5 mM 0.5540 mL 2.7699 mL 5.5397 mL
10 mM 0.2770 mL 1.3849 mL 2.7699 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
CTID: NCT06050512
Phase: Phase 1/Phase 2    Status: Withdrawn
Date: 2024-11-19
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
CTID: NCT03763162
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-10
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
CTID: NCT02253316
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-01
Selinexor and Backbone Treatments of Multiple Myeloma Patients
CTID: NCT02343042
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-19
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
CTID: NCT03225417
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-08-30
View More

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
CTID: NCT03283917
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-08-15


Ixazomib Rollover Study
CTID: NCT02924272
Phase: Phase 2    Status: Completed
Date: 2024-08-05
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
CTID: NCT04217967
Phase: Phase 4    Status: Completed
Date: 2024-08-01
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
CTID: NCT02916771
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-18
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
CTID: NCT03439293
Phase: Phase 2    Status: Completed
Date: 2024-07-03
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
CTID: NCT05451771
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-06-28
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
CTID: NCT03587662
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-24
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
CTID: NCT03942224
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-21
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
CTID: NCT02697383
Phase: Phase 1    Status: Completed
Date: 2024-05-13
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
CTID: NCT03590652
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-01
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
CTID: NCT04837131
Phase: Phase 2    Status: Terminated
Date: 2024-04-26
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CTID: NCT01659658
Phase: Phase 3    Status: Terminated
Date: 2024-04-25
Bone Healing During Ninlaro Exposure
CTID: NCT04028115
Phase: Phase 2    Status: Completed
Date: 2024-04-03
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
CTID: NCT04052880
Phase: Phase 2    Status: Recruiting
Date: 2024-03-28
Ixazomib + Pomalidomide + Dexamethasone In MM
CTID: NCT04094961
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-03-12
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
CTID: NCT03817320
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-02-22
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
CTID: NCT04047797
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-02-21
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD)
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (KarMMa-3)
CTID: null
Phase: Phase 3    Status: Ongoing, Trial now transitioned, GB - no longer in EU/EEA, Completed
Date: 2019-05-13
A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing
Date: 2019-03-04
A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-09-28
A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-08-01
A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA, Completed
Date: 2017-10-26
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2017-06-19
Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease
CTID: null
Phase: Phase 1, Phase 2    Status: Ongoing
Date: 2017-03-14
Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd):
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-11-17
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies.
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2016-10-27
Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)
CTID: null
Phase: Phase 1, Phase 2    Status: Prematurely Ended
Date: 2016-08-31
Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years eligible for High Dose Therapy: a phase II study of the Intergroupe Francophone du Myélome (IFM)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-04-27
A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenolidomide and bortezomib.
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2015-09-28
Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-01-19
HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2014-09-19
A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplant in patients with newly-diagnosed, symptomatic multiple myeloma.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-07-07
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2014-06-17
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CTID: jRCT2080223632
Phase:    Status: completed
Date: 2017-08-29
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance)'Relapsed/Refractory Multiple Myeloma'
CTID: jRCT1080223537
Phase:    Status: completed
Date: 2017-05-24
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
CTID: jRCT2080222821
Phase:    Status: completed
Date: 2015-04-16
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
CTID: jRCT2080222474
Phase:    Status: completed
Date: 2014-04-25
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
CTID: jRCT2080222296
Phase:    Status: completed
Date: 2013-11-18
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
CTID: jRCT2080222296
Phase:    Status: completed
Date: 2013-11-18
A Phase 1 Study of MLN9708 in Japanese Patients with Relapsed and/or Refractory Multiple Myeloma
CTID: jRCT2080221780
Phase:    Status: completed
Date: 2012-04-26

Biological Data
  • IXAZOMIB (MLN2238)

    Proteasome inhibition and antitumor activity of bortezomib and MLN2238 in tumor xenograft models of activated B-cell diffuse large B-cell lymphoma.Clin Cancer Res.2011 Dec 1;17(23):7313-23.
  • IXAZOMIB (MLN2238)

    Osteolytic bone disease in the iMycCα/Bcl-XL GEM model of de novo PCM.Clin Cancer Res.2011 Dec 1;17(23):7313-23.
  • IXAZOMIB (MLN2238)

    Antitumor activity of bortezomib and MLN2238 in the disseminated mouse model of DP54-Luc iMycCα/Bcl-XL PCM.Clin Cancer Res.2011 Dec 1;17(23):7313-23.
  • IXAZOMIB (MLN2238)

  • IXAZOMIB (MLN2238)

  • IXAZOMIB (MLN2238)


Contact Us